Abstract
The last few years have seen the transfer of two decades of research into Chimeric Antigen Receptors (CARs) into clinical trials. Despite this extensive research, there is still a great deal of debate into the optimal design strategy for these, primarily, anti-cancer entities. The archetypal CAR consists of a single-chain antibody fragment, specific to a tumour- associated antigen, fused to a component of the T-cell receptor complex (typically CD3ζ) which on antigen binding primes the engrafted T-cell for anti-tumour activity. The modular nature of these artificial receptors has enabled researchers to modify aspects of their structure, including the extracellular spacer, transmembrane and cytoplasmic domain, to achieve laboratory defined optimal activity. Despite this there is no consensus on the optimal structure, a problem exacerbated by conflicting results using identical receptors. In this review, we provide a structural overview of CAR development and highlight areas that require further refinement. We also attempt to identify possible reasons for conflicting results in the hope that this information will inspire future rational design strategies for optimal tumour targeting using CARs.
Keywords: CD3ζ, T-cell Receptor, immunotherapy, gene-transfer, T-cell, costimulation, cancer, scFv
Current Gene Therapy
Title: Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy
Volume: 10 Issue: 2
Author(s): John S. Bridgeman, Robert E. Hawkins, Andreas A. Hombach, Hinrich Abken and David E. Gilham
Affiliation:
Keywords: CD3ζ, T-cell Receptor, immunotherapy, gene-transfer, T-cell, costimulation, cancer, scFv
Abstract: The last few years have seen the transfer of two decades of research into Chimeric Antigen Receptors (CARs) into clinical trials. Despite this extensive research, there is still a great deal of debate into the optimal design strategy for these, primarily, anti-cancer entities. The archetypal CAR consists of a single-chain antibody fragment, specific to a tumour- associated antigen, fused to a component of the T-cell receptor complex (typically CD3ζ) which on antigen binding primes the engrafted T-cell for anti-tumour activity. The modular nature of these artificial receptors has enabled researchers to modify aspects of their structure, including the extracellular spacer, transmembrane and cytoplasmic domain, to achieve laboratory defined optimal activity. Despite this there is no consensus on the optimal structure, a problem exacerbated by conflicting results using identical receptors. In this review, we provide a structural overview of CAR development and highlight areas that require further refinement. We also attempt to identify possible reasons for conflicting results in the hope that this information will inspire future rational design strategies for optimal tumour targeting using CARs.
Export Options
About this article
Cite this article as:
S. Bridgeman John, E. Hawkins Robert, A. Hombach Andreas, Abken Hinrich and E. Gilham David, Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy, Current Gene Therapy 2010; 10 (2) . https://dx.doi.org/10.2174/156652310791111001
DOI https://dx.doi.org/10.2174/156652310791111001 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Linezolid Activity Against Disseminated Listeria monocytogenes Meningitis and Central Nervous System Abscesses: Focus on Early Drug Myelotoxicity
Current Drug Safety Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics The Bioactive Potential of Culturable Fungal Endophytes Isolated From the Leaf of <i>Catharanthus roseus</i> (L.) G. Don
Current Topics in Medicinal Chemistry Radiology of Oropharyngeal Cancer - Institutional Experience and Literature Review -
Current Cancer Therapy Reviews Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect
Current Gene Therapy The Roles of miR-25 and its Targeted Genes in Development of Human Cancer
MicroRNA Combined Treatment with Laser Ablation and Tyrosine-Kinase Inhibitor as A Novel Multimodality Approach to Locally Advanced Thyroid Cancer: A Case Report
Endocrine, Metabolic & Immune Disorders - Drug Targets Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery Synthesis of Novel Imine Stilbene Analogs Exhibiting Potent Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Application of Electroporation in DNA Vaccination Protocols
Current Gene Therapy Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents
Current Protein & Peptide Science How does the Selection of Laboratory Mice Affect the Results of Physiological Distribution of Radiopharmaceuticals?
Current Radiopharmaceuticals Cancer Regulator MicroRNA: Potential Relevance in Diagnosis, Prognosis and Treatment of Cancer
Current Medicinal Chemistry Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Cornea: Window to Ocular Immunology
Current Immunology Reviews (Discontinued) A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer
Current Drug Metabolism